Target type: molecularfunction
Binding to a major histocompatibility complex class II molecule; a set of molecules displayed on cell surfaces that are responsible for lymphocyte recognition and antigen presentation. [GOC:jl]
MHC class II proteins are integral membrane glycoproteins that play a critical role in the adaptive immune response by presenting processed antigens to CD4+ T lymphocytes. Their molecular function involves a complex series of steps that ultimately enable the recognition of foreign peptides by T cells, leading to the activation of immune responses.
1. **Antigen Processing:**
- MHC class II molecules are synthesized in the endoplasmic reticulum (ER) and associate with a chaperone protein called invariant chain (Ii).
- Ii prevents the premature binding of peptides to MHC class II molecules in the ER.
- The MHC class II-Ii complex travels to the endosomal compartment where it encounters antigens.
- Ii is degraded, leaving a small fragment called CLIP (class II-associated invariant chain peptide) bound to the peptide binding groove of MHC class II.
- The CLIP is then exchanged for exogenous peptides that are derived from degraded proteins taken up by antigen-presenting cells (APCs).
2. **Peptide Binding:**
- The peptide binding groove of MHC class II molecules is a shallow, open cleft that can accommodate peptides of varying lengths and sequences.
- The groove is lined with polymorphic residues, which contribute to the diversity of MHC class II molecules and their ability to bind a wide range of peptides.
- Peptide binding is a highly specific process, and MHC class II molecules typically bind peptides that have a particular anchor residue motif.
- Anchor residues are amino acids in the peptide that interact with specific pockets in the peptide binding groove.
3. **T Cell Recognition:**
- Once an MHC class II molecule has bound a peptide, it is transported to the cell surface and presented to CD4+ T lymphocytes.
- CD4+ T cells express the T cell receptor (TCR), which can recognize the peptide-MHC class II complex.
- The TCR binds to the MHC class II molecule and the bound peptide, initiating a signaling cascade within the T cell.
4. **T Cell Activation and Immune Response:**
- The activation of CD4+ T cells leads to the production of cytokines, which can promote the differentiation of other immune cells, such as cytotoxic T lymphocytes (CTLs), and the activation of the adaptive immune response.
- The activated T cells can also differentiate into memory cells, providing long-lasting immunity against specific pathogens.
In summary, the molecular function of MHC class II protein binding involves antigen processing, peptide binding, T cell recognition, and ultimately the activation of the adaptive immune response. This process is essential for the recognition and elimination of foreign pathogens, and plays a critical role in maintaining immune homeostasis.'
"
Protein | Definition | Taxonomy |
---|---|---|
HLA class II histocompatibility antigen gamma chain | An MHC class II histocompatibility antigen gamma chain that is encoded in the genome of human. [PRO:WCB, UniProtKB:P04233] | Homo sapiens (human) |
T-cell surface glycoprotein CD4 | A CD4 molecule that is encoded in the genome of human. [PRO:DNx, UniProtKB:P01730] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
crizotinib | crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER. | 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |
complestatin | chloropeptin II : A heterodetic cyclic peptide consisting of N-acylated trytophan, 3,5-dichloro-4-hydroxyphenylglycine, 4-hydroxyphenylglycine, 3,5-dichloro-4-hydroxyphenylglycyl, tyrosine and 4-hydroxyphenylglycine residues joined in sequence and in which the side-chain of the central 4-hydroxyphenylglycine residue is attached to the side-chain of the tryptophan via a C3-C6 bond and to the side-chain of the tyrosine via an ether bond from C5. It is isolated from the culture broth of Streptomyces and has anti-HIV-1 activity. complestatin: compound extracted from Streptomyces lavendulae mycelia; on acid hydrolysis yields D-4-hydroxyphenylglycine & D-3,5-dichloro-4-hydroxyphenylglycine & acidic chromophore; inhibits gp120-CD4 binding isocomplestatin : A heterodetic cyclic peptide which is a atropisomer of complestatin. It is isolated from the culture broth of Streptomyces and has anti-HIV-1 activity. | cyclic ether; heterodetic cyclic peptide; indoles; organic heterobicyclic compound; organochlorine compound; peptide antibiotic; polyphenol | anti-HIV-1 agent; antimicrobial agent; HIV-1 integrase inhibitor; metabolite |
pf-06463922 | lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer. lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein | aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles | antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |